



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Statement of Unaudited Financial Results for the Quarter and Six Months ended 30.09.2013 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
		30-09-2013	30-06-2013	30-09-2012	30-09-2013	30-09-2012	31-03-2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	45749.04	36150.94	50582.52	81899.98	90995.73	167324.71
	Less : Excise Duty	1597.38	1669.68	1108.49	3267.06	2166.70	4843.28
	Net Sales	44151.66	34481.26	49474.03	78632.92	88829.03	162481.43
	(b) Other Operating Income	6.89	6.53	52.77	13.42	114.62	143.67
	Total Income from Operations (net)	44158.55	34487.79	49526.80	78646.34	88943.65	162625.10
2.	Expenses						
	(a) Cost of Materials consumed	31105.68	24567.84	36940.47	55673.52	61207.09	114652.24
	(b) Purchase of Stock in Trade	520.22	2736.95	990.62	3257.17	4490.48	5999.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(810.18)	(2948.51)	(331.98)	(3758.69)	1149.03	(6440.21)
	(d) Employee benefits expense	1256.49	1398.7	1149.93	2655.19	2224.99	4861.11
	(e) Depreciation and amortisation expense	2098.93	2139.51	1919.59	4238.44	3712.19	7595.61
	(f) Other expenses	4443.18	2924.94	3678.50	7368.12	6734.80	14544.15
	Total Expenses	38614.32	30819.43	44347.13	69433.75	79518.58	141212.70
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	5544.23	3668.36	5179.67	9212.59	9425.07	21412.40
4.	Other Income	429.04	398.86	412.71	827.90	824.70	1604.03
5.	Profit before finance costs and exceptional Items (3+4)	5973.27	4067.22	5592.38	10040.49	10249.77	23016.43
6.	Finance costs	3941.79	2576.78	2767.91	6518.57	5260.68	11548.93
7.	Profit after finance costs but before exceptional Items (5-6)	2031.48	1490.44	2824.47	3521.92	4989.09	11467.50
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2031.48	1490.44	2824.47	3521.92	4989.09	11467.50
10.	Tax Expense	513.83	382.82	569.53	896.65	1131.38	2900.95
11.	Net Profit from ordinary activities after tax (9-10)	1517.65	1107.62	2254.94	2625.27	3857.71	8566.55
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1517.65	1107.62	2254.94	2625.27	3857.71	8566.55
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	84,517.96
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.68	0.49	1.01	1.17	1.72	3.82
	b) Diluted	0.68	0.49	1.01	1.17	1.72	3.82
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.68	0.49	1.01	1.17	1.72	3.82
	b) Diluted	0.68	0.49	1.01	1.17	1.72	3.82

Part II Select Information for the Quarter and six month ended 30.09.2013

A	Particulars of shareholding						
1.	Public Shareholding						
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35	44.35	44.35

B	Investor Complaints	3 Months ended 30.09.2013					
	Pending at the beginning of Quarter	-					
	Received During the Quarter	18					
	Disposed Off During the Quarter	18					
	Pending at the end of Quarter	-					

Statement of Assets and Liabilities		(Rs in Lacs)	
PARTICULARS		As at 30-09-2013	As at 31-03-2013
		Unaudited	Audited
SHAREHOLDERS' FUND			
(I) Capital		2,242.61	2,242.61
(ii) Reserves and Surplus		87,243.22	84,517.96
NON CURRENT LIABILITIES			
(i) Long Term Liabilities		22,826.92	26,096.08
(ii) Deffered Tax Liability		10,094.02	9,575.63
(ii) Other Long Term Liabilities		85.49	102.99
(iii) Long Term Provisions		378.88	378.88
CURRENT LIABILITIES			
(i) Short Term Borrowings		54,013.97	50,911.14
(ii) Trade Payables		41,995.39	38,251.85
(iii) Other Current Liabilities		13,583.67	13,127.61
(iv) Short Term Provisions		2,945.94	2,199.56
		235,410.11	227,404.31

NON CURRENT ASSETS

(i) Fixed Assets (Incl CWIP)	105,730.07	105,240.84
(ii) Non Current Investments	5.01	5.01
(iii) Long Term Loans & Advances	7,408.65	7,048.61
(iv) Other Non Current Assets	1.31	1.50

CURRENT ASSETS

(i) Current Investments	31.92	31.92
(ii) Inventories	75,583.36	67,600.04
(iii) Trade Receivables	37,891.91	34,938.64
(iv) Cash & Bank Balances	333.10	624.04
(v) Short Term Loans & Advances	6,111.03	8,684.33
(vi) Other Current Assets	2,313.75	3,229.38

235,410.11	227,404.31
-------------------	-------------------

Notes:

- 1 The above financial results were reviewed by Audit Committee on 12.11.13 and approved by the Board in its meeting held on even date i.e. 13.11.13 and further limited reviewed by the Statutory Auditors of the Company.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 The Shareholders in their Annual General Meeting held on 30.09.2013 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2012-13. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- 4 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 5 As per Accounting Standard 11, accounting of the effect of changes in foreign exchange rates will be ascertained at the end of the year and hence the same is not considered in these quarterly results.
- 6 The above financial results are on stand alone basis.

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

Dated: 13.11.2013

Place: Chandigarh

(Dinesh Dua)

Chief Executive Officer & Director